

Case Report

Ulcerative colitis presenting with recurrent alternating bowel habits and rectal bleeding in a young female: a case report

Sahr Abdelrahman Elhardalo*, Eman A. Abuhzaima

Primary Health Care Corporation, Qatar

Received: 21 May 2025

Accepted: 12 July 2025

*Correspondence:

Dr. Sahr Abdelrahman Elhardalo,
E-mail: saelhardalo@phcc.gov.qa

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Ulcerative colitis (UC) is a chronic inflammatory bowel disease that mostly affects the colon and rectum. The condition frequently causes symptoms such as diarrhoea, abdominal pain and rectal bleeding. Additionally, the delayed diagnosis is common because UC symptoms often mimic those of other conditions, such as haemorrhoids and IBS. This report underscores the need for timely diagnosis and intervention, based on clinical, endoscopic, and biomarker testing, including the use of fecal calprotectin. A 24-year-old female presented to her primary care provider with complaints of alternating bowel habits complaints, lower abdominal pain and rectal bleeding. She was initially misdiagnosed as having haemorrhoids and IBS with no systemic conditions suspected. Lab testing showed normal C-reactive protein (CRP <5 mg/l) and normal results on complete blood count (WBC $4.2 \times 10^9/l$, haemoglobin 13.2 g/dl, platelets $250 \times 10^9/l$, RBC $4.8 \times 10^{12}/l$). Fecal calprotectin levels were notably high at 1035 µg/g; normal <50 µg/g). A colonoscopy revealed a diagnosis of distal proctitis that was classified as Mayo score 3. The first-line treatment included the use of mesalamine both orally and as a topical agent. Clinical improvement and reduced fecal calprotectin (34 µg/g) were reported during follow-up, reflecting gastrointestinal mucosal healing and a positive response to therapy. The usefulness of fecal calprotectin as a key biomarker in the evaluation of disease progression in UC is highlighted by this case. Appropriate diagnosis along with early mesalamine treatment contributed to symptoms relief and mucosal recovery. Immediate care is important in reducing complications and promoting patient recovery.

Keywords: Ulcerative colitis, Inflammatory bowel disease, Fecal calprotectin, Mesalamine, Early diagnosis

INTRODUCTION

Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) that is characterized by persistent inflammatory processes of the mucosa within the colon beginning at the rectum and extending proximally.¹ The global incidence of UC in 2023 was estimated to be 5 million cases, with the number of new cases increasing on a global scalen.¹ Most UC cases are diagnosed in young adults where the onset peak is between 15 and 30 years. A second yet smaller peak occurs within the age span of 50-70 years.² Both men and women suffer from the disease, but studies show that men over 45 years have an increased risk developing UC.³ The development of UC is determined by a group of genetic susceptibility, environmental triggers, and

dysregulation of the immune system. Bloody diarrhoea, abdominal discomfort, and the urgency of defecation are commonly found in UC patients.⁴ The severity of UC differs between individuals. The disease can range from mild to severe with remission and relapse. Mayo score is frequently used for the evaluation of severity of the disease, considering clinical symptoms, endoscopic evidence and physician's assessment.^{1,4} About 10-15% of patients have an aggressive course, whereas the majority have mild to moderate course.⁵ Extra-intestinal manifestations (EIMs) are frequent in UC patients that affect organs outside the gastrointestinal tract. 25-40% of the patients with IBD have EIMs that may affect the joints, skin, eyes, liver, and kidneys.⁶ Skin-related EIMs include erythema nodosum and pyoderma gangrenosum while

ocular manifestations involve the uveitis and episcleritis. In the joints, peripheral arthritis and ankylosing spondylitis likely to occur.⁷ Initial evaluation tests include a complete blood count (CBC) for anemia or leukocytosis, a serum C-reactive protein (CRP) to see the extent of systemic inflammation and stool test to rule out infections like *Clostridioides difficile*.⁸ Another biomarker that could enable the diagnosis of IBD, including UC, is fecal calprotectin.⁹ Most importantly, colonoscopy with biopsy continues to be the gold standard for diagnosing UC. The endoscopic examination shows characteristic mucosal inflammation and a biopsy confirms the histopathological features, including cryptitis and crypt abscesses, that are indicative of UC.^{10,11} UC is sometimes associated with a number of other gastrointestinal disorders, such as IBS and haemorrhoids. IBS is a functional disorder of the gastrointestinal tract defined as pain and alteration of bowel habits without underlying inflammation, and haemorrhoids are swollen blood vessels in the rectum or anus that may present with rectal bleeding.^{12,13} Misdiagnosis of UC as IBS or haemorrhoids is common, as approximately 10% of IBD patients were misdiagnosed with IBS, 3% of which prolonged for more than five years.¹⁴

For mild to moderate UC, amino salicylates, such as mesalazine are preferred because of anti-inflammatory properties.¹⁵ For moderate to severe cases, biologic agents are used. These include anti-tumor necrosis factor (TNF) therapies (e.g., infliximab, adalimumab), integrin inhibitors (e.g., vedolizumab), interleukin inhibitors (e.g., ustekinumab), and Janus kinase (JAK) inhibitors (e.g., tofacitinib).¹⁶ Emerging therapies, including etrasimod, a sphingosine-1-phosphate receptor modulator, have shown promise in clinical trials.¹⁷ Regular monitoring can also help assess treatment efficacy and detect early signs of relapse. Fecal calprotectin levels serve as a non-invasive biomarker for intestinal inflammation, aiding in the differentiation between IBD and irritable bowel syndrome.¹⁸ This case report aims to highlight the importance of early diagnosis and appropriate management in UC.

CASE REPORT

A 24-year-old female presented to primary care with a history of chronic abdominal pain and recurrent alternating bowel habits. The patient reported fresh blood per rectum, and her current symptoms had been associated with haemorrhoids and IBS previously. The patient denied history of oral ulcers, fever, clubbing, rashes, uveitis, jaundice and arthritis etc. She denied having a history of iron deficiency anemia or significant pre-existing medical problems. She was a single university student, had no sexual relationship, did not smoke and did not drink alcohol. She was underweight, with a BMI of 17, but in general her physical health was good. She had no paleness or jaundice. The findings of abdominal examination revealed a soft, non-distended abdomen with no superficial or deep masses, and there was no evidence for chronic liver

disease. The patient refused to undergo a rectal examination. Laboratory results suggested that C-reactive protein (CRP) was within normal values, and at levels below 5 mg/l, indicating minimum systemic inflammation. Complete blood count (CBC) was also normal with white blood cell count= $4.2 \times 10^9/l$, haemoglobin=13.2 g/dl, platelets= $250 \times 10^9/l$, and red blood cells count= $4.8 \times 10^{12}/l$. However, a stool occult blood test came back positive. Additionally, fecal calprotectin was markedly elevated at 1035 $\mu\text{g/g}$ (normal range: $<50 \mu\text{g/g}$), which suggested possible inflammation in the gastrointestinal tract. Both celiac screen and *Helicobacter pylori* testing were negative.

The patient was referred to a gastrointestinal specialist for further evaluation, and a colonoscopy and esophagogastroduodenoscopy (EGD) were performed. The colonoscopy showed distal proctitis, with a Mayo score of 3, indicating moderate disease activity. Rectal biopsy revealed cryptitis, crypt abscesses, and increased lamina propria cellularity with a lymphoplasmacytic infiltrate, all consistent with IBD, most likely ulcerative colitis. Based on these findings, the patient was started on oral and topical amino salicylates (5-aminosalicylic acid, or mesalamine). After initiating treatment, the patient showed significant clinical improvement, with a notable reduction in symptoms. Follow-up laboratory tests showed a dramatic decrease in fecal calprotectin levels to 34 $\mu\text{g/g}$ (normal: $<50 \mu\text{g/g}$), suggesting a reduction in intestinal inflammation. The patient's progress continued, with both clinical and laboratory improvements indicating a positive response to therapy.

DISCUSSION

In this case report, a 24-year-old woman was first diagnosed with haemorrhoids and IBS, but later on, a correct diagnosis of UC was made. All combined, high fecal calprotectin, cryptitis, crypt abscesses, and increased lamina propria cellularity significantly contributed to diagnosis. Amino salicylate therapy resulted in relief of the symptoms and confirmed the diagnosis of UC.¹⁵ Fecal calprotectin is a non-invasive marker of intestinal neutrophil activity and helps in distinguishing between inflammatory and functional bowel diseases.⁹ Increased concentrations of fecal calprotectin are associated with active inflammation in UC. The high fecal calprotectin value, 1035 $\mu\text{g/g}$, pointed strongly to active UC in the case. Scientific bases approve that FC greater than 250 $\mu\text{g/g}$ indicate active disease and higher FC levels are usually associated with higher severity.¹⁹ This finding is also in line with previous research reporting associations between increased FC and endoscopic measures of infection in UC patients.²⁰ At the start of treatment, the FC levels of the patients were 34 $\mu\text{g/g}$. These findings highlight the necessity to improve clinical protocols in order to integrate FC measurements for assessment of disease severity.²¹ Also, fecal calprotectin levels may help detect mucosal healing, which emphasizes its importance as a tool for assessing the treatment response.²² Ye et al conducted the

meta-analysis reporting that UC patients achieved histological remission having fecal calprotectin levels less than 100 mc/g.^{22,23} Abdominal pain, diarrhoea and rectal bleeding are the most common symptoms observed in patients with UC. The initial misdiagnosis of UC demonstrates the difficulties in differentiating it from gastrointestinal disorders such as IBS, which share the same symptomatology without an inflammatory element. Studies show the importance of FC testing to distinguish between IBD and IBS as increased FC values indicate inflammatory state.²⁴

Mayo score is one of the most common tests to assess the activity of UC. The Mayo score comprises four components stool frequency, rectal bleeding, endoscopic findings and overall physician's assessment (all are scored from 0 to 3 with their synthetic score ranging from 0 to 12). A high score indicates an increased disease activity.²⁵ In their study involving a cohort of 2,608 UC patients, Naegeli et al demonstrated the efficacy of the full and partial Mayo Scores as alternatives to endoscopy and physician's global assessment, determining them to be practical surrogates for analyzing the degree of disease activity in patients and clinical studies.²⁶ Apart from the full Mayo score, the Mayo endoscopic sub score (MES) to predict long-term outcomes in UC has also been employed. A study by Xu et al of 280 UC patients showed that increase in MES is associated with increased risk of malignant transformation thus highlighting the prognostic importance of endoscopic evaluation in UC.²⁷

In our case presented, patient was initiated on a combination of oral and rectal amino salicylates as the first line therapy in the management of UC. This approach is based on clinical guidelines that advocate the use of 5-aminosalicylic acid (5-ASA) preparations in mild-moderate UC, particularly if the disease is limited to the distal colon (28). The return to normal bowel routine verifies the expected outcome of administering therapy with 5-ASA preparations. A similar case presented a 16-year-old girl diagnosed to have ulcerative colitis presented initially with bloody diarrhea and abdominal pain, which were later confirmed by colonoscopy and biopsy. The utility of Mesalamine therapy resulted in remission, which underlined the effectiveness of 5-ASA therapies in the treatment of pediatric ulcerative colitis.²⁸ A case report of a seven-year-old Nigerian girl with UC who presented with bloody diarrhoea and weight loss emphasizes the need for prompt intervention to protect against growth retardation and malnutrition.²⁹ Another case study described a 29-year-old patient with ulcerative colitis with the presenting features of diffuse vascular loss and superficial ulceration throughout her colon. Histopathological test results indicated chronic inflammation with cryptitis, crypt abscesses, and crypt architectural distortion.³⁰ This example demonstrates the variability in the manifestation of UC, emphasizing the need for a detailed diagnostic approach, the endoscopic and histopathological evaluations, to confirm UC. In another case presented by Scheller et al, a 23-year-old

female with UC was successfully treated on the 5-Rs gut restoration program, encompassing removing, replacing, re-inoculating, repairing, and rebalancing. Nevertheless, after over six weeks without the use of the mesalamine suppositories, the patient became asymptomatic, which indicates that dietary and lifestyle changes can supplement pharmacological approaches in the management of UC.³¹ Timely and proactive UC management can improve the outcomes of patients significantly. Delayed diagnosis and treatment are indicative of higher risk of disease progression, complications, and of a lower quality of life.²⁰ As seen in this case, timely initiation of proper therapy is capable of clinical improvement and mucosal healing, as shown by reduction in fecal calprotectin levels.^{16,32}

CONCLUSION

The case highlights the importance of early diagnosis and individualized approaches in UC management. From the patient's initial symptoms of abdominal pain, alternating bowel movement, rectal bleeding, and elevated fecal calprotectin, a timely diagnosis of UC was established. The efficacy of amino salicylate therapy in mild to moderate UC is reflected in the improvement of bowel habits and a decrease of fecal calprotectin levels. The case demonstrates that fecal calprotectin is a pivotal non-invasive biomarker for assessing disease activity and determining the effectiveness of various treatments.

Further studies should be directed towards improving biomarkers such as fecal calprotectin for diagnosing disease earlier and the development of new treatments that target specific inflammatory mechanisms in UC. Long-term studies are necessary to determine whether early mucosal healing can actually have reduced risk of colorectal cancer and unnecessary surgery.

Funding: No funding sources

Conflict of interest: None declared

Ethical approval: Not required

REFERENCES

1. Le Berre C, Honap S, Peyrin-Biroulet L. Ulcerative colitis. *The Lancet*. 2023;402(10401):571-84.
2. Gajendran M, Loganathan P, Jimenez G, Catinella AP, Ng N, Umaphathy C, et al. A comprehensive review and update on ulcerative colitis. *Disease-a-Month*. 2019;65(12):100851.
3. Gros B, Kaplan GG. Ulcerative Colitis in Adults: A Review. *JAMA*. 2023;330(10):951-65.
4. Segal JP, LeBlanc J-F, Hart AL. Ulcerative colitis: an update. *Clinical Medicine*. 2021;21(2):135-9.
5. Fumery M, Singh S, Dulai PS, Gower-Rousseau C, Peyrin-Biroulet L, Sandborn WJ. Natural history of adult ulcerative colitis in population-based cohorts: a systematic review. *Clin Gastroenterol Hepatol*. 2018;16(3):343-56.
6. Al-Quorain AA. Extraintestinal manifestations of inflammatory bowel disease. *Medknow*; 2019: 65.

7. Rogler G, Singh A, Kavanaugh A, Rubin DT. Extraintestinal manifestations of inflammatory bowel disease: current concepts, treatment, and implications for disease management. *Gastroenterology*. 2021;161(4):1118-32.
8. Wenzel A, Gold BD, Strople J. Laboratory evaluation of inflammatory bowel disease. *Pediatric Inflammatory Bowel Dis*. 2023;229-44.
9. Wang W, Cao W, Zhang S, Chen D, Liu L. The Role of Calprotectin in the Diagnosis and Treatment of Inflammatory Bowel Disease. *International J Mol Sci*. 2025;26(5):1996.
10. Limdi JK, Farraye FA. An update on surveillance in ulcerative colitis. *Curr Gastroenterol Rep*. 2018;20:1-12.
11. Malik A, Nadeem M, Javaid S, Malik MI, Enofe I, Abegunde AT. Estimating the optimum number of colon biopsies for diagnosing microscopic colitis: a systematic review. *European J Gastroenterol Hepatol*. 2022;34(7):733-8.
12. Ng QX, Soh AYS, Loke W, Lim DY, Yeo W-S. The role of inflammation in irritable bowel syndrome (IBS). *Journal of inflammation research*. 2018;345-9.
13. Nallajerla S, Ganta S. A comprehensive review on hemorrhoids a recto anal disorder. *Pharmacology*. 2021;1:270-82.
14. Card TR, Siffledeen J, Fleming KM. Are IBD patients more likely to have a prior diagnosis of irritable bowel syndrome? Report of a case-control study in the General Practice Research Database. *United European Gastroenterol J*. 2014;2(6):505-12.
15. Nakashima J, Patel P, Preuss CV. Mesalamine (USAN). *StatPearls: StatPearls Publishing*; 2024.
16. D'Amico F, Parigi TL, Bonovas S, Peyrin-Biroulet L, Danese S. Long-term safety of approved biologics for ulcerative colitis. *Expert Opin Drug Safety*. 2020;19(7):807-16.
17. Choi D, Becker M, Ivanov M, Bhat S. Etrasimod: A sphingosine-1-phosphate receptor modulator for the treatment of ulcerative colitis. *Ann Pharmacoth*. 2024;58(10):1054-63.
18. Sarhan RSR, Marei YM, Marei YM. Evaluation of the diagnostic performance of estimated fecal calprotectin and serum intelectin-1 and C-reactive protein solo or in combination for differentiation between patients with query ulcerative colitis and irritable bowel syndrome. *The Egyptian J Int Med*. 2023;35(1):79.
19. Kristensen V, Røseth A, Ahmad T, Skar V, Moum B. Fecal calprotectin: a reliable predictor of mucosal healing after treatment for active ulcerative colitis. *Gastroenterol Res Pract*. 2017;20(1):2098293.
20. Zamani H, Barzin G, Yousefinia M, Mohammadkhani A, Ostovaneh MR, Sharifi AH, et al. Diagnostic value of fecal calprotectin in patient with ulcerative colitis. *Middle East J Digest Dis*. 2013;5(2):76.
21. Chen F, Hu Y, Fan Y-H, Lv B. Clinical value of fecal calprotectin in predicting mucosal healing in patients with ulcerative colitis. *Front Med*. 2021;8:679264.
22. Steinsbø Ø, Aasprong OG, Aabakken L, Karlsen LN, Grimstad T. Fecal calprotectin correlates with disease extent but remains a reliable marker of mucosal healing in ulcerative colitis. *Official J American Coll Gastroenterol*. 2009;7:9900.
23. Ye X, Wang Y, Wang HHX, Feng R, Ye Z, Han J, et al. Can fecal calprotectin accurately identify histological activity of ulcerative colitis? A meta-analysis. *Therap Adv Gastroenterol*. 2021;14:1756284821994741.
24. Güven B, İssi F, Sağ E, Buruk K, Çakır M. Impact of fecal calprotectin measurement for inflammatory bowel disease in children with alarm symptoms. *Ped Inflamm Bowel Dis*. 2022;7:792.
25. Kawakatsu S, Zhu R, Zhang W, Tang MT, Lu T, Quartino AL, et al. A longitudinal model for the Mayo Clinical Score and its sub-components in patients with ulcerative colitis. *J Pharmacok Pharmacody*. 2022;49(2):179-90.
26. Naegeli AN, Hunter T, Dong Y, Hoskin B, Middleton-Dalby C, Hetherington J, et al. Full, partial, and modified permutations of the Mayo score: characterizing clinical and patient-reported outcomes in ulcerative colitis patients. *Crohn's & colitis 360*. 2021;3(1):37.
27. Xu W, Liu F, Tang W, Gu Y, Zhong J, Cui L, et al. The Mayo endoscopic score is a novel predictive indicator for malignant transformation in ulcerative colitis: a long-term follow-up multicenter study. *Front Surg*. 2022;9:832219.
28. Md.Salma MDS, Y.Siva YS, Narendra JB. Case Report on Ulcerative Colitis in 16 year girl. *World J Curr Med Pharma Res*. 2020;6:287-90.
29. Senbanjo IO, Oshikoya KA, Onyekwere CA, Abdulkareem FB, Njokanma OF. Ulcerative colitis in a Nigerian girl: A case report. *BMC Research Notes*. 2012;5:1-4.
30. Vuyyuru SK, Jairath V, Hanžel J, Ma C, Feagan BG. Case report: medical management of acute severe ulcerative colitis. *Gastroenterol Hepatol*. 2023;19(10):621.
31. Scheller B, Winter C, Zamyad J, Felmlee K, Heard D. The Successful Management Of Ulcerative Colitis With A Nutritional Intervention: A Case Report. *Integrat Med Clin J*. 2019;18(5):40.
32. D'Amico F, Fiorino G, Solitano V, Massarini E, Guillo L, Allocca M, et al. Ulcerative colitis: Impact of early disease clearance on long-term outcomes-A multicenter cohort study. *United European Gastroenterol J*. 2022;10(7):775-82.

Cite this article as: Elhardalo SA, Abuhzaima EA. Ulcerative colitis presenting with recurrent alternating bowel habits and rectal bleeding in a young female: a case report. *Int J Res Med Sci* 2025;13:3471-4.